Sage, Biogen

Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.
Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' best interests.
No deal: Sage rejects Biogen's buyout offer, scouts for strategic alternatives
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. | The company's board of directors unanimously rejected partner Biogen's $469 million buyout proposal,
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.
Sage Therapeutics Rejects Biogen’s $469M Offer, Citing Undervaluation
Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal significantly undervalues the company and does not align with shareholder interests.
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up
Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from drug giant Biogen BIIB to acquire the remaining shares of SAGE. Per Sage Therapeutics,
Sage Sues Partner Biogen After Unsolicited Takeover Offer
Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital Markets.
Lyon coach Pierre Sage has been fired despite putting the French league club back on track
Lyon coach Pierre Sage has been fired despite leading the French league club out of a crisis last season and having the team ...
Sage Group rises Tuesday, still underperforms market
Sage Group PLC closed 1.08% below its 52-week high of £13.42, which the company achieved on January 22nd.
Sage Hill girls basketball emerges as candidate for CIF-SS Open Division playoffs
The Lightning are eighth in the section’s latest computer-generated power ratings, a key spot since the Open has featured ...
BioPharma Dive1d
Sage rebuffs Biogen bid to take it over
Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...
Sage Group rises Wednesday, outperforms market
Shares of Sage Group PLC SGE inched up 0.68% to £13.37 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.28% to ...
American Banker1d
Sage Capital Bank hopes digital banking upgrade fosters growth
A partnership with fintech Apiture will give the bank new online and mobile banking services by the end of 2025.
Hosted on MSN2h
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...
Blue Sage Capital Successfully Closes an Oversubscribed and Over Hard Cap Fund IV - $618 Million Fund More than Double the Size of the Prior Fund
Blue Sage Capital raised Fund IV without a placement agent and engaged Kirkland and Ellis as fund counsel. With Fund IV ...